Quest Diagnostics (DGX) Set to Release Earnings on Thursday

by · The Markets Daily

Quest Diagnostics (NYSE:DGX – Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Thursday, October 22nd. Analysts expect Quest Diagnostics to announce earnings of $2.87 per share and revenue of $3.05 billion for the quarter. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Individuals may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 22, 2026 at 8:30 AM ET.

Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, beating analysts’ consensus estimates of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The business had revenue of $3.04 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same quarter last year, the business earned $2.62 earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. On average, analysts expect Quest Diagnostics to post $11.15 EPS for the current fiscal year and $11.97 EPS for the next fiscal year.

Quest Diagnostics Price Performance

Shares of NYSE:DGX opened at $234.92 on Tuesday. The stock has a market cap of $25.93 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 2.13 and a beta of 0.54. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46. Quest Diagnostics has a 12 month low of $171.18 and a 12 month high of $248.84. The stock’s 50 day moving average price is $237.35 and its 200 day moving average price is $215.75.

Quest Diagnostics Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be paid a dividend of $0.86 per share. The ex-dividend date of this dividend is Tuesday, October 6th. This represents a $3.44 annualized dividend and a yield of 1.5%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 36.52%.

Analysts Set New Price Targets

DGX has been the subject of a number of research analyst reports. Argus set a $260.00 price target on shares of Quest Diagnostics in a report on Wednesday, July 29th. Wall Street Zen upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. Barclays lifted their price objective on shares of Quest Diagnostics from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Weiss Ratings upgraded shares of Quest Diagnostics from a “buy (a-)” rating to a “buy (a)” rating in a report on Tuesday, October 6th. Finally, Truist Financial boosted their target price on shares of Quest Diagnostics from $250.00 to $260.00 and gave the stock a “hold” rating in a report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $238.23.

View Our Latest Report on DGX

Insider Activity

In other news, SVP Michael E. Prevoznik sold 22,677 shares of Quest Diagnostics stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $243.11, for a total value of $5,513,005.47. Following the transaction, the senior vice president directly owned 37,557 shares of the company’s stock, valued at $9,130,482.27. This trade represents a 37.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total transaction of $2,427,200.00. Following the completion of the transaction, the chief executive officer directly owned 122,423 shares in the company, valued at approximately $29,714,510.56. This trade represents a 7.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 34,277 shares of company stock valued at $8,316,493 over the last three months. Insiders own 0.88% of the company’s stock.

Quest Diagnostics Company Profile

(Get Free Report)

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.

Featured Stories